Peginterferon Beta-1A

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Peginterferon Beta-1A
   1. Pharmacist Assessment Report
   2. Peginterferon Beta-1A: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Peginterferon Beta-1A: Known uses and market status in Australia

Summary

The TxGNN model produced candidate indications for Peginterferon Beta-1A with a score of 0.99 or higher. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication for this drug. The one known use is supported by a licence in another country.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
relapsing-remitting multiple sclerosis	licence in another country (approved indication: multiple sclerosis)

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
10212L	Plegridy	Single use injection pen containing 125	Valid

Safety Considerations

• Drug Interactions: The interaction screen returned 100 potential interactions. The compiled data lists only 20 of them: one is rated Major and the remainder Moderate.
  • Major: Bupropion
  • Moderate (examples): Acarbose, pioglitazone, rosiglitazone, clarithromycin, levofloxacin, minocycline, naltrexone, rosuvastatin, simvastatin, oxandrolone, oxymetholone, pegvaliase, orlistat, clotrimazole, nicotinamide, chenodeoxycholic acid, picosulfuric acid, sodium sulfate, and polyethylene glycol (3350 with electrolytes)

Warnings and contraindications were not available in the compiled data. Please refer to the TGA-approved Product Information (PI) for these.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---